Nevertheless, the response rate (RR) of ICI monotherapy for ALK-positive lung cancer ranges between 0 and 8%; therefore, it is generally considered to be ineffective.[11,12] In ALK-positive lung cancer, median PFS is 3.9 months in ALK-TKI-naive patients and 1.5 months in posttreatment patients, with limited efficacy with ICIs.[13]. This evidence concerns the gene ALK and lung cancer.